ATLANTA--(BUSINESS WIRE)--Feb. 22, 2006--Serologicals Corporation (NASDAQ:SERO) today announced financial results for the fourth quarter of our fiscal year ended January 1, 2006 (fiscal 2005). Revenues for the fourth quarter increased 26.0%, to $87.1 million, compared to $69.2 million in the same period last year, while revenues for fiscal 2005 increased 40.3%, to $274.9 million, compared to $195.9 million in our fiscal year ended January 2, 2005 (fiscal 2004). Diluted earnings (loss) per share from continuing operations were $(0.39) and $0.02 per share for the fourth quarter and fiscal 2005, respectively, compared to $0.12 and $0.59 per share for the same periods in fiscal 2004. The fourth quarter and fiscal 2005 results reflect one-time charges totaling $39.4 million, comprised of $38.0 for impairment and exiting costs and $1.4 million for inventory write-offs, arising primarily from our decision to close manufacturing facilities in Toronto by mid-2006 and our decision not to open a facility in Lawrence, Kansas. The fourth quarter and fiscal 2004 results reflect a one-time charge of $3.2 million for in process research and development arising from the acquisition of Upstate Group, Inc. in October 2004.
